Women who develop a subtype of intrahepatic cholestasis of pregnancy (ICP) marked by jaundice — a yellowing of the skin or whites of the…
News
FATTY LIVER DISEASE
NewsTargeting SEMA3A protein could help slow MASLD: Study
A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate in the livers of people…
BILIARY ATRESIA
NewsNeurotensin may be new blood biomarker of biliary atresia
Levels of neurotensin, a small protein highly present in the gastrointestinal tract, are higher than normal in the blood and liver of biliary atresia…
HEPATITIS
NewsImdusiran plus immunotherapy may help in chronic hepatitis B
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…
CHOLESTASIS
NewsAbuse suspected for skin bruising in case of PFIC2 liver disease
An 8-month-old girl with type 2 progressive familial intrahepatic cholestasis (PFIC2) who was seen at a hospital emergency department with extensive skin bruising was suspected…
FATTY LIVER DISEASE
NewsBlood levels of GDF15 protein may help in liver cancer risk of MASLD
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…
ALAGILLE SYNDROME
NewsLivmarli sustains benefit for Alagille patients over 7 years: Trial data
Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of clinical studies continued to experience…
HEPATITIS
NewsBJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
FATTY LIVER DISEASE
NewsGlobal Fatty Liver Day to raise awareness of ‘concealed epidemic’
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
CHOLANGITIS
NewsSeladelpar still eases itch, liver damage after 2 years: PBC trial
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…
Recent Posts
- Breastmilk helps babies recover after Kasai surgery, study shows
- Bepirovirsen under review in Europe as a treatment for chronic hepatitis B
- ALF marks Donate Life Month in April with focus on living liver donors
- Why we might cancel a doctor’s appointment (and why we shouldn’t)
- Inflammation markers may predict fetal risk in ICP: Study